Re-administration of EGFR-TKI to mutated EGFR NSCLC patients after remission of osimertinib induced ILD

Background null Osimertinib is a key-drug to treat NSCLC harboring EGFR sensitizing mutation at 1st line setting as well as T790M resistant mutation at late line. Interstitial lung disease/pneumonitis (ILD) is a fatal adverse event induced by tyrosine kinase inhibitors including osimertinib especially in the Japanese patients. On the other hand, transient asymptomatic pulmonary opacities (TAPO) caused by osimertinib were reported as relatively...